The company has an extensive patent portfolio covering extraction and preservation of DNA and RNA for downstream processing by qPCR, RT-qPCR and sequencing. Arcis launched Arcis Sample Prep and Arcis Blood kit in 2016, with a Pathogen kit launched in 2017, and further new product launches in the product development pipeline. Arcis offers a quick, simple, low resource option in comparison to existing technologies on the market – making it ideal for point of care or field based testing. Arcis has been awarded Innovate grants for detection of nucleic acid material from plants and the company has recently been awarded a Biocatalyst feasibility grant to stabilise RNA from urine which is anticipated will lead to a simpler and more convenient diagnostic test for prostate cancer from urine and eliminate the need for an invasive examination. Arcis is also working closely with a number of molecular pathogen testing companies to integrate the Arcis extraction technology into their chemistry and detection processes.
Professor Steve Howell
Professor Howell has over 20 years’ life science commercialisation experience, supporting companies’ development and profitability. He founded Innova Partnerships in 2006, where he has been instrumental in creating over a dozen life science start-ups and raised in excess of £100m in financing. Steve oversaw the exit of Innova Biosciences in 2016-2017 to SYGNIS AG, Innova Partnerships’ second exit. He has held positions at Unilever plc, and was previously Director of Business Development at Alere Inc. and Research Director at Unipath Ltd. In 2015 he was made Visiting Professor of Commercial Innovation at King’s College, London.
Before joining Arcis Nick was CEO of Biomatrica where he led the development of biomarker collection products and the subsequent sale of the company to Exact Sciences Corporation. He previously spent over 20 years with Life Technologies (now Thermo Fisher Scientific) as Vice President and General Manager of several global business units supplying pharma and diagnostics companies with instrument and reagent components for their gene and cell therapies and diagnostic systems. Earlier roles included Vice President of Sales, Americas of Upstate Biotechnology (now Millipore Sigma) and before that, General Manager, Latin America of Invitrogen (now Thermo Fisher Scientific). He holds an MBA from Harvard Business School and a B.S. from Ohio State University.
Peter joined Arcis in March 2011. A Qualified Chartered Accountant with Ernst Young by background and prior global roles with Cable
& Wireless and Fortune Brands Inc. Peter was a key member of the Executive Team of SSL International leading the Innovation &
Technology teams, and was heavily involved in the trade sale of SSL to Reckitt Benckiser for £2.54 billion in late 2010.
Dr Jan Rogers
Jan joined Arcis in March 2011 and has extensive knowledge of the development and commercialisation of innovative medical
devices. She has held senior R&D positions at London International Group, Regent Medical, Molnlycke Healthcare, Convatec Inc and
SSL International before joining Arcis Biotechnology. Jan has a PhD in Surface Chemistry from the University of Reading and an MBA
specializing in Innovation from the University of Bath.
The Arcis technology has received a great deal of interest in a wide range of markets ranging from human pathogen, biodefense, clinical research, veterinary diagnostics, plant genomics and food safety. This has resulted in a number of successful collaborations. If you would like to collaborate with Arcis Biotechnology or look at integrating our products into your workflow please contact us.
Arcis Biotechnology’s main investor –Calculus- invested in Arcis Biotechnology due to their impressive suite of technologies and the wide range of potential applications in different markets.
Arcis is headed by Nick Ecos, CEO, Peter Whitehurst, COO, and Dr Jan Rogers, CSO. Nick was the CEO of Biomatrica prior to sale of the company to Exact Sciences Corporation. Peter and Jan were previously key members of the SSL International executive team prior to its sale to Reckitt Benckiser for £2.54bn in 2010.
Arcis are looking to raise up to £3.0m equity investment. We have already raised £1.95m in this round, from existing and new investors, at a pre-money evaluation of £18.5m
If you would like to invest in Arcis Biotechnology please contact Peter Whitehurst [email protected].